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The proteinase-activated receptors (PARs) are widely recognized for their modulatory 
properties of infl  ammation and neurodegeneration. We investigated the role of PAR2 in the 
pathogenesis of multiple sclerosis (MS) in humans and experimental autoimmune encepha-
lomyelitis (EAE) in mice. PAR2 expression was increased on astrocytes and infi  ltrating 
macrophages in human MS and murine EAE central nervous system (CNS) white matter 
(P < 0.05). Macrophages and astrocytes from PAR2 wild-type (WT) and knockout (KO) mice 
exhibited differential immune gene expression with PAR2 KO macrophages showing signifi  -
cantly higher interleukin 10 production after lipopolysaccharide stimulation (P < 0.001). 
PAR2 activation in macrophages resulted in the release of soluble oligodendrocyte cyto-
toxins (P < 0.01). Myelin oligodendrocyte glycoprotein–induced EAE caused more severe 
infl  ammatory gene expression in the CNS of PAR2 WT animals (P < 0.05), together with 
enhanced T cell proliferation and interferon 𝗄 production (P < 0.05), compared with KO 
littermates. Indeed, PAR2 WT animals showed markedly greater microglial activation and 
T lymphocyte infi  ltration accompanied by worsened demyelination and axonal injury in the 
CNS compared with their PAR2 KO littermates. Enhanced neuropathological changes were 
associated with a more severe progressive relapsing disease phenotype (P < 0.001) in WT 
animals. These fi  ndings reveal previously unreported pathogenic interactions between CNS 
PAR2 expression and neuroinfl  ammation with ensuing demyelination and axonal injury.
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Proteinase-activated receptors (PARs) are a 
family of G protein–coupled receptors that 
are widely expressed on neurons and glial cells 
in the nervous system (1). PARs are activated 
through proteolytic cleavage of their extracel-
lular NH2 terminus. The proteolytic cleavage 
unmasks a “tethered ligand” that binds intra-
molecularly to the receptor and initiates a sig-
nal transduction event (2). Among the four 
PARs identifi  ed to date, PAR1, PAR3, and 
PAR4 can be activated by thrombin, whereas 
trypsin and mast cell tryptase can activate 
PAR2 (2, 3). Signaling through diff  erent het-
erotrimeric G proteins, PARs can aff  ect vari-
ous cellular functions in the nervous system, 
including neural cell proliferation, gene tran-
scription, diff  erentiation, and survival (4, 5). 
The role of PAR2, which is widely distributed 
throughout the nervous system, has been prin-
cipally investigated in the peripheral nervous 
system, where it is known to play major roles 
in injury, infl  ammation, neuronal signaling, 
and nociception (6, 7). PAR2 is also known to 
be expressed on neurons and astrocytes in 
  rodent and human central nervous systems 
(CNS), and several studies have implicated it 
in the pathogenesis of ischemia and neurode-
generation (8–10).426  PAR2 MODULATES NEUROINFLAMMATION IN MS AND EAE | Noorbakhsh et al.
Multiple sclerosis (MS) is a common immune-mediated 
neurological disorder, which is histopathologically character-
ized by infi  ltration of the CNS with infl  ammatory leukocytes 
followed by demyelination and axonal loss (11–13). It is gen-
erally accepted that an autoimmune response directed against 
components of myelin is the chief pathogenic event during 
MS (14). The exact mechanisms leading to the generation of 
autoimmune responses in MS are not fully known, although 
components of both the adaptive and innate immune systems 
are involved (15, 16). Experimental autoimmune encephalo-
myelitis (EAE) is a widely studied animal model for MS, 
which recapitulates many of the clinical and neuropathologic 
aspects of MS (17). EAE can be induced by immunization 
of genetically susceptible animals with diff  erent antigenic 
Figure 1.  PAR2 is increased in the CNS white matter of MS patients. 
(A) PAR2 mRNA levels were increased in CNS white matter of MS patients 
(n = 6) compared with non-MS patients (n = 6), but (B) trypsin  ogen 
mRNA levels were not signifi  cantly different between the two groups. 
RFC, relative fold change. Student’s t test; *, P < 0.05. (C) PAR2 immuno-
reactivity was present on perivascular and parenchymal (C, inset) cells in 
MS white matter, but not in non-MS (D) CNS tissues. Immu  nolabeling 
with the anti-CD45 (E) or the anti-GFAP antibodies (F) revealed colocal-
ization of PAR2 on leukocytes and astrocytes in CNS white matter of 
MS patients in the areas of active demyelination. Original magnifi  cation, 
400. (G) Flow cytometric analysis of PBMCs from healthy donors disclosed 
the expression of PAR2 on resting and PHA-stimulated monocytes, 
whereas (H) expression levels were minimal on resting or PHA-treated 
lymphocytes. BV, blood vessel. JEM VOL. 203, February 20, 2006  427
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  components of CNS myelin, including myelin basic protein 
(MBP), proteolipid protein, or myelin oligodendrocyte gly-
coprotein (MOG). Immunization leads to the generation of 
myelin-reactive T cells in the periphery, which then migrate 
into the CNS and initiate autoimmune infl  ammation. Al-
though considered largely a T cell–mediated disease, there is 
increasing evidence for the involvement of other immune 
cells, including activated macrophages and microglia in both 
the initiation as well as the eff  ector phases of the immune re-
sponse associated with the EAE and MS pathogenesis (16, 
18). Herein, the expression levels and the cell types express-
ing PAR2 were investigated in the CNS of MS and control 
patients. Using EAE as an animal model of MS, we explored 
the role of PAR2 activation on astrocytes and monocytoid 
cells. Experiments were performed to evaluate the impact of 
PAR2-defi  cient signaling on the generation and responsive-
ness of myelin-reactive T cells and the severity of MOG-
  induced EAE.
RESULTS
PAR2 expression is increased in the white matter during 
MS and EAE
PAR2 has been shown to be widely expressed on neurons 
and astrocytes in the CNS (19, 20). To investigate the role of 
PAR2 in the neuroinfl  ammatory process associated with MS, 
we examined PAR2 transcript levels in CNS white matter 
from MS and non-MS patients. RT-PCR analysis showed 
signifi  cantly higher PAR2 transcript levels in the white mat-
ter of MS compared with non-MS patients (Fig. 1 A). Tran-
script levels of trypsinogen, a potential PAR2-activating 
proteinase, were not diff  erent between MS and non-MS 
CNS tissues (Fig. 1 B). Immunohistochemical staining 
showed that PAR2 immunoreactivity was markedly enhanced 
in MS (Fig. 1 C) compared with non-MS white matter 
(Fig. 1 D). In MS CNS tissues, PAR2 immunoreactivity was 
chiefl  y detected on infi  ltrating perivascular cells together 
with parenchymal glial cells in the areas of active demyelin-
ation (Fig. 1 E). Indeed, PAR2 immunoreactivity was colo-
calized with CD45 leukocyte/macrophage marker in 
perivascular cells (Fig. 1 E) and with glial fi  brillary acidic pro-
tein (GFAP) astrocytic marker in parenchymal cells (Fig. 1 F). 
PAR2 immunoreactivity was present on neurons in the gray 
matter with no obvious diff  erences between groups (not 
  depicted). Previous studies of blood-derived mononuclear cells 
have reported that monocytes but not lymphocytes express 
PAR2, and moreover, the expression levels increase upon 
diff  erentiation to macrophages (21, 22). We also examined 
PAR2 expression in PBMCs from healthy human   volunteers. 
Figure 2.  PAR2 expression is up-regulated during EAE on CNS 
  astrocytes and leukocytes. (A) PAR2 mRNA levels were increased in the 
CNS of mice with EAE (n = 8) as compared with healthy controls (n = 8). 
(B) Trypsinogen mRNA levels were not signifi  cantly different between the 
two groups of animals. RFC, relative fold change. Student’s t test; 
*, P < 0.05. (C) PAR2 was colocalized with GFAP immunoreactivity on 
astrocytes (top) and Iba-1 immunoreactivity on macrophages/microglia in 
the lumbar spinal cord during EAE. Original magnifi  cation, 400.428  PAR2 MODULATES NEUROINFLAMMATION IN MS AND EAE | Noorbakhsh et al.
Flow cytometric analysis showed PAR2 expression on the 
monocyte population (Fig. 1 G), whereas expression on lym-
phocytes was minimal (Fig. 1 H). Treatment of PBMC cul-
tures with phytohemagglutinin for 24 h resulted in a marked 
up-regulation of PAR2 immunoreactivity on monocytes (Fig. 
1 G), but the PAR2 immunoreactivity on the lymphocyte 
population was unaff  ected (Fig. 1 H). Thus, these observa-
tions indicated that monocytes rather than lymphocytes were 
the chief cell type expressing PAR2 in both blood and brain, 
in support of previous studies (21, 22).
Given that the EAE animal model recapitulates many of 
the neuropathological and clinical features of MS, together 
with similar underlying pathogenic mechanisms, we next ex-
amined PAR2 expression in the CNS of mice with EAE. 
  Interestingly, RT-PCR analysis showed signifi  cantly higher 
levels for PAR2 mRNA in the CNS of animals with EAE 
compared with healthy control mice (Fig. 2 A). Similar to the 
MS CNS samples, PAR2 immunoreactivity was detectable in 
the white matter of EAE animals, where it was localized 
chiefl  y on GFAP-immunopositive astrocytes (Fig. 2 C, top) 
and ionized calcium binding adaptor protein (Iba-1)–immuno-
positive macrophage/microglia (Fig. 2 C, bottom). Hence, 
these fi  ndings indicated that PAR2 expression was up-regulated 
on both glial cells and infi  ltrating leukocytes during MS/
EAE-associated neuroinfl  ammation.
PAR2 defi  ciency regulates immune gene expression 
in macrophages and astrocytes
Previous studies have demonstrated important roles for PAR2 
in modulating infl  ammatory processes in the central and pe-
ripheral nervous systems (23, 24). As macrophage/microglial 
activation followed by subsequent demyelination and astro-
cytosis are predominant neuropathologic features of MS and 
EAE (25), we investigated the eff  ects of PAR2 expression on 
the production of infl  ammatory mediators by these cells. Af-
ter LPS treatment for 8 h, mRNA levels of proinfl  ammatory 
or antiinfl  ammatory mediators TNF-α (Fig. 3 A), IL-1β (Fig. 
3 B), inducible nitric oxide synthase (iNOS) (Fig. 3 C), and 
IL-10 (Fig. 3 D) were analyzed in primary astrocytes and 
macrophages from PAR2 WT and KO mice. Similar levels 
of TNF-α (Fig. 3 A), IL-1β (Fig. 3 B), and iNOS (Fig. 3 C) 
mRNA were observed in PAR2 WT and KO macrophages. 
However, PAR2-defi  cient macrophages showed signifi  cantly 
higher levels of IL-10 mRNA after LPS treatment (Fig. 3 D). 
Gene expression analysis also showed signifi  cantly higher 
  levels of iNOS mRNA (Fig. 3 G) in PAR2 WT astrocytes after 
LPS treatment, whereas TNF-α (Fig. 3 E), IL-1β (Fig. 3 F), 
and IL-10 (Fig. 3 H) levels did not diff  er between WT and 
KO astrocytes. Thus, these observations revealed a diff  erence 
in the expression of immune genes between PAR2 WT and 
KO astrocytes and macrophages, which depended on the 
  individual cell type.
PAR2 activation mediates oligodendrocyte toxicity
Acute demyelinating lesions in MS are believed to be gen-
erated by infi   ltrating leukocytes and activated microglia 
that destroy myelin in the presence of autoreactive T cells 
(26, 27). However, oligodendrocyte injury and apoptosis, 
even in the absence of a substantial infl  ammatory reaction, 
have also been reported to be a principal pathological fea-
ture in newly forming lesions (28, 29). We investigated the 
indirect eff  ects of PAR2 activation on macrophages and as-
trocytes in terms of oligodendrocyte viability. Supernatants 
from cultured murine macrophages or astrocytes, treated 
with the PAR2-activating peptide (PAR2 AP) SLIGRL-
NH2 or the mutant inactive peptide (mAP) LSIGRL-NH2, 
were applied to oligodendrocyte cultures for 24 h, and the 
surface area of GalC-immunopositive oligodendrocytes as 
well as the number of cells with processes were quanti-
fi  ed. Interestingly, supernatants of PAR2 AP–treated, but 
not mAP- or mock-treated macrophages, caused a marked 
reduction in the surface area of exposed oligodendrocytes, 
leaving a higher number of cells with fewer or no pro-
cesses (Fig. 4 A). Quantifi  cation of the oligodendrocyte area 
and the number of cells with processes showed signifi  cant 
reductions in cultures treated with the supernatants from 
Figure 3.  PAR2 defi  ciency regulates immune gene expression in 
macrophages and astrocytes. PAR2 WT and KO macrophages showed 
similar levels of TNF-α (A), IL-1β (B), and iNOS (C) expression after stimu-
lation with LPS, but (D) PAR2 KO macrophages show signifi  cantly higher 
levels of IL-10 expression compared with WT cells. mRNA levels of TNF-α 
(E), IL-1β (F), and IL-10 (H) are not signifi  cantly different between PAR2 WT 
and KO astrocytes, whereas (G) iNOS mRNA levels are signifi  cantly higher 
in WT astrocytes after LPS stimulation. All experiments were performed in 
triplicate. RFC, relative fold change. Student’s t test; ***, P < 0.001.JEM VOL. 203, February 20, 2006  429
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PAR2 AP–stimulated macrophages compared with mock- 
or mAP-treated macrophages (Fig. 4 B). Conversely, su-
pernatants of PAR2 AP–treated astrocytes did not aff  ect 
oligodendrocyte morphology and surface area (Fig. 4 C). 
Gene expression studies revealed a signifi  cant induction of 
TNF-α (Fig. 4 D), iNOS (Fig. 4 E), IL-6 (Fig. 4 F), and 
IL-12p40 (Fig. 4 G) transcript levels in PAR2 AP–treated 
macrophages compared with mAP- or mock-treated cells. 
In   addition, IL-1β, IFN-inducible protein 10, monocyte 
chemoattractant protein 1, and macrophage infl  ammatory 
protein 1α transcripts were increased signifi  cantly in PAR2 
AP–treated macrophages, but not in mAP- or mock-treated 
cells (not depicted). The same eff  ects were not observed 
for PAR2 AP–treated astrocytes (not depicted). Thus, these 
fi  ndings revealed that direct activation of PAR2 on mac-
rophages caused oligodendrocyte injury associated with 
infl  ammatory gene expression, which might contribute to 
demyelination in MS.
PAR2 defi  ciency reduces neuroinfl  ammation and T cell 
proliferation during EAE
Given the higher expression of PAR2 in human MS CNS 
white matter and its contribution to infl  ammatory gene ex-
pression and oligodendrocyte injury, we next investigated 
the potential role of PAR2 in EAE, as an animal model of 
MS, using PAR2 WT and KO mice. We examined MOG-
  induced EAE in 10–12-wk-old PAR2 KO mice compared with 
their WT littermate controls and corresponding healthy (  intact) 
controls. Neuropathological examination of the CNS of WT 
animals with EAE showed markedly enhanced immuno-
reactivity for macrophage/microglial marker, Iba-1, com-
pared with PAR2 KO EAE animals and the   nonimmunized 
Figure 4.  PAR2 activation on macrophages but not astrocytes 
mediates oligodendrocyte toxicity and immune gene expression. 
(A) Supernatants of PAR2 AP–treated but not mAP- or mock-treated 
macrophages decreased oligodendrocyte process extension. Original 
magnifi  cation, 600. (B) Quantifi  cation of oligodendrocyte surface area 
and the number of cells with processes showed a signifi  cant reduction 
in cells exposed to the supernatants from PAR2 AP–treated macro-
phages but not (C) astrocytes. (D) Treatment of macrophages with PAR2 
AP but not mAP induced TNF-α, (E) iNOS, (F) IL-6, and (G) IL-12p40 
transcript expression. RFC, relative fold change. Tukey-Kramer Multiple 
Comparisons test; **, P < 0.01; ***, P < 0.001. All experiments were 
performed in triplicate.430  PAR2 MODULATES NEUROINFLAMMATION IN MS AND EAE | Noorbakhsh et al.
intact group (Fig. 5 A, fi  rst column). Iba-1–immunopositive 
cells showed hypertrophy and were more frequently detected 
in WT and PAR2 KO EAE groups compared with the qui-
escent morphology observed in the nonimmunized intact 
group. Quantitative analysis showed a signifi  cantly higher 
number of Iba-1–immunopositive cells in the PAR2 WT EAE 
group compared with PAR2 KO EAE animals (Fig. 5 B). 
MBP immunoreactivity showed disrupted integrity of the 
myelin in both PAR2 WT and KO EAE groups with much 
more severe demyelination in WT animals (Fig. 5 A,   second 
column), as indicated by quantitative analysis of MBP-
immuno  positive areas of the white matter (Fig. 5 C). Indeed, 
myelin loss was closely associated with macrophage infi  ltra-
tion/microglial activation, as indicated by merged MBP–Iba-1 
immunoreactivity (Fig. 5 A, third column). CD3+ T cells 
were also detectable in spinal cords after EAE induction (Fig. 
5 A, fourth column), with the WT EAE group showing a sig-
nifi  cantly higher number of positive cells compared with KO 
EAE animals (Fig. 5 D). Silver staining followed by counting 
of the axonal number also showed a signifi  cant reduction in 
the number of axons in the PAR2 WT EAE group compared 
with the KO EAE and control groups (Fig. 5 E). Of note, 
PAR2 WT and KO nonimmunized (intact) animals did not 
diff  er in terms of neuropathological features and therefore 
were pooled for these quantitative analyses. Overall, these 
fi   ndings indicated that defi  cient  PAR2 signaling reduced 
neuroinfl  ammation with greater preservation of myelin and 
proximate axons in the CNS during MOG-induced EAE.
The generation of myelin-reactive T cells in the periph-
eral immune system with their subsequent infi  ltration of the 
CNS has been considered a key event in EAE and MS patho-
genesis (11). To examine the proliferative and cytokine re-
sponse of T cells in MOG-immunized PAR2 WT and KO 
animals, we measured [3H]thymidine incorporation and in-
tracellular IFN-γ immunoreactivity by FACS in lymphocytes 
cocultured with MOG-loaded irradiated splenocytes. Prolif-
eration of T cells measured by [3H]thymidine incorporation 
was signifi  cantly higher in WT animals compared with their 
PAR2 KO littermates (Fig. 6 A). Intracellular cytokine assays 
showed a signifi  cant increase in IFN-γ reactivity of CD3:
CD4 but not CD3:CD8 immunopositive lymphocytes of 
WT animals compared with PAR-2 KO littermates (Fig. 6, 
B and C). These observations disclosed that despite the ab-
sence of PAR2 on lymphocytes, there was a signifi  cant dif-
ference in T cell reactivity at the level of proliferative and 
cytokine responses after MOG immunization of WT and 
KO animals.
Enhanced host immune responses are apparent within 
the CNS during MS and EAE (13). Gene expression studies 
of WT and KO animals showed signifi  cantly higher levels of 
TNF-α (Fig. 7 A), iNOS (Fig. 7 B), IL-6 (Fig. 7 C), and 
IFN-γ (Fig. 7 D) mRNA in the CNS of WT animals with 
Figure 5.  PAR2 defi  ciency diminishes CNS infl  ammatory 
cell infi  ltration, demyelination, and axonal loss during EAE 
  induction. (A) WT EAE animals showed higher number of Iba-1+ cells 
(fi  rst column), associated with worsened demyelination (second and third 
columns), and a higher number of CD3-immunopositive lymphocytes 
(fourth column) compared with littermate KO EAE or intact animals. 
Silver staining displayed more axonal injury/loss in WT EAE animals (fi  fth 
column) compared with KO EAE or intact animals. (B) Quantifi  cation 
of macrophage/microglial, (C) myelin, (D) lymphocyte reactivity, and 
(E) axonal counts showed signifi  cantly higher infl  ammatory cell infi  ltra-
tion together with more severe demyelination and axonal loss in WT EAE 
animals. All quantitative analyses represented the results of four animals 
per group. Tukey-Kramer Multiple Comparisons test; *, P < 0.05; **, P < 0.01; 
***, P < 0.001. Error bars represent standard errors.JEM VOL. 203, February 20, 2006  431
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EAE compared with their PAR-2 KO littermates. TNF-α, 
iNOS, IL-6, and IFN-γ mRNA was detectable in PAR2 
WT and KO animals without EAE (intact) with no diff  er-
ence between the two groups (Fig. 7, A–D). Together with 
  diff  erences in the neuropathological fi  ndings and T cell 
  reactivity, these observations emphasized the role of PAR2-
  defi   cient signaling in mitigating MOG-induced autoim- 
mune processes.
PAR2 defi  ciency is neuroprotective during EAE
Consistent with the diff  erences in infl  ammatory gene expres-
sion, T cell response, and neuropathologic fi  ndings in EAE 
induced in PAR2 WT and KO animals, we observed a sig-
nifi  cant diff  erence in the neurobehavioral phenotype severity 
between PAR2 WT and KO animals after the induction of EAE. 
Displaying a progressive relapsing disease course (Fig. 8 A), 
PAR2 WT animals showed a signifi  cantly earlier disease onset 
together with signifi  cantly more severe neurological disabil-
ity during the course of the disease. In addition, maximal 
  disease score (Fig. 8 B) and cumulative neurological disability 
(Fig. 8 C) were signifi  cantly higher for WT EAE animals 
compared with the KO EAE group. Hence, our fi  ndings 
  indicated that PAR2 expression contributed to the severity of 
neuroinfl  ammation and neurological disability during MOG-
induced EAE.
DISCUSSION
This study highlights previously unrecognized interactions be-
tween PAR2 expression and induction of neuroinfl  ammation 
during MS/EAE, thereby disclosing new therapeutic oppor-
tunities for CNS autoimmune demyelinating disorders. We 
have demonstrated that PAR2 expression is enhanced in the 
CNS white matter during MS and EAE in which it is chiefl  y 
expressed on perivascular macrophages and astrocytes (Fig. 9). 
PAR2 WT and defi  cient macrophages and astrocytes exhib-
ited diff  erential infl  ammatory gene expression, with PAR2 
activation on macrophages leading to the induction of pro-
infl  ammatory cytokines and chemokines adversely aff  ecting 
oligodendrocyte viability (Fig. 9).   Indeed, absent PAR2 sig-
naling suppressed EAE disease severity, which was associated 
with decreased T cell reactivity and neuroinfl  ammation.
It is widely recognized that autoreactive T cells infi  ltrat-
ing  the white matter during MS initiate demyelination 
through the release of toxins together with recruiting and acti-
vating  monocytoid cells (16). However, an alternative 
view holds that oligodendrocyte death, perhaps due to apop-
tosis, together with microglial activation in the absence of 
marked lymphocyte infi  ltration might herald newly  forming 
de  myelinating lesions (29). Indeed, several studies   indicate 
Figure 7.  PAR2 expression is associated with greater CNS infl  amma-
tory gene expression during EAE induction. mRNA levels of (A) TNF-α, 
(B) iNOS, (C) IL-6, and (D) IFN-γ were signifi  cantly higher in the CNS of 
PAR2 WT animals with EAE (n = 5) compared with their KO littermates 
with EAE (n = 5) and intact animals (n = 4) for each genotype. RFC, 
  relative fold change. Tukey-Kramer Multiple Comparisons test; *, P < 0.05.
Figure 6.  T cells from PAR2 WT animals show greater proliferation 
and IFN-𝗄 production. (A) Lymphocytes isolated from lymph nodes of 
MOG-immunized WT animals (n = 4) show higher [3H]thymidine incorpo-
ration after coculture with MOG-loaded irradiated splenocytes compared 
with lymphocytes from immunized littermate KO animals (n = 4). 
(B and C) CD3:CD4-immunopositive cells from WT animals show higher 
levels of IFN-γ production after coculture with MOG-loaded splenocytes 
compared with the same population in KO animals. Student’s t test; 
*, P < 0.05. Error bars represent standard errors.432  PAR2 MODULATES NEUROINFLAMMATION IN MS AND EAE | Noorbakhsh et al.
that   innate immune mechanisms are potent determinants of 
MS and EAE disease onset and severity (30–33). Extensive 
oligodendrocyte death likely overwhelms normal mecha-
nisms of dead cell clearance, prompting a T cell–mediated 
infl  ammatory response that arises from the release of myelin 
antigens (29). In this study, we observed less T cell reactivity 
and infi  ltration after EAE induction in PAR2-defi  cient mice, 
which may partly explain the milder disease severity in this 
group of animals compared with their WT littermates. None-
theless, we also found that PAR2 activation on macrophages 
led to the production of soluble cytotoxic factors, which di-
minished oligodendrocyte viability. These two observa-
tions could be considered reciprocal mechanisms by which 
PAR2 expression aff  ects the underlying pathogenic processes 
in EAE, likely refl  ecting the interaction of the adaptive and 
innate   immune systems. However, it is also plausible that 
PAR2 expression and activation on monocytoid cells (unlike 
astrocytes) contributes directly to oligodendrocyte injury 
(34), which could prime a subsequent myelin-specifi  c T 
cell response, as mentioned above.
A recent study has reported a neuroprotective role for 
neuronal PAR2 in experimental stroke (35). Moreover, our 
group showed a neuroprotective role for neuronal PAR2 
expression and activation in the context of HIV-induced de-
mentia, a neurodegenerative disorder caused by the HIV in-
fection of brain (24). Herein, up-regulation and activation of 
PAR2 on monocytoid cells contributed to the neuroinfl  am-
matory/degenerative process in EAE. Of interest, PAR2 ex-
pression is up-regulated on monocytes upon diff  erentiation to 
macrophages (22), and its activation leads to the production 
of proinfl  ammatory cytokines IL-1β, IL-6, and IL-8 (21). 
A concomitant localized increase in tryptic serine proteinases, 
which act as potential activators of PAR2, may accentuate 
PAR2-mediated eff  ects in the context of MS/EAE neuroin-
fl  ammation. Indeed, there is also a report describing the role 
of PAR2 in dendritic cell development (36), indicating that 
dendritic cells do not spontaneously develop from the bone 
marrow cells of PAR2-defi  cient mice after IL-4/GM-CSF 
Figure 8.  PAR2 signaling exacerbates EAE severity. (A) Neurobehav-
ioral analysis during EAE showed a later onset accompanied by less severe 
EAE disease in PAR2 KO animals compared with their WT littermates. 
(B) Likewise, the maximum disease score during the disease course and 
(C) cumulative neurological disability was signifi  cantly lower in PAR2 KO 
animals compared with WT littermate controls during EAE. Student’s 
t test; **, P < 0.01; ***, P < 0.001. Error bars represent standard errors.
Figure 9.  PAR2’s neuroinfl  ammatory actions in the CNS during 
MS/EAE. Activation of PAR2 on macrophages and astrocytes results in 
the release of proinfl  ammatory (NO, TNF-α, IL-1β, and IL-6) and oligo-
dendrocytotoxic molecules together with chemokines that contribute to 
the recruitment of myelin-reactive T lymphocytes into the CNS during 
MS/EAE. JEM VOL. 203, February 20, 2006  433
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treatment, despite diff  erentiating to mature dendritic cells in 
the presence of infl  ammatory mediators (36). In our hands, 
treatment of bone marrow cells from WT and PAR2 KO 
animals with IL-4/GM-CSF led to the generation of mor-
phologically indistinguishable dendritic cells, which matured 
normally after LPS treatment (not depicted). Nonetheless, 
given the administration of adjuvants upon MOG immuni-
zation with the resulting immune activation, it is unlikely 
that diff  erences in antigen presentation exert major eff  ects on 
the ensuing autoimmune processes in the present studies.
Although many studies have indicated proinfl  ammatory 
roles for PAR2 in respiratory, gastrointestinal, musculo-
skeletal, skin, and peripheral nervous systems (23, 37–42), 
PAR2 agonists have also been shown to be benefi  cial in some 
mouse models of mucosal infl  ammation (43, 44). These stud-
ies underscore the diff  erent roles played by PAR2 based on 
the individual cell type and specifi  c animal model or disease 
context. Elucidation of mechanisms leading to altered recep-
tor expression and diff  erential downstream eff  ects, together 
with identifying specifi  c activating proteinases, will permit 
the development of new therapeutic strategies for modulating 
detrimental eff  ects of infl  ammation in the nervous system.
MATERIALS AND METHODS
Human brain tissue samples. CNS tissue (frontal lobe white matter) was 
collected at autopsy with consent from each experimental group (MS, n = 6; 
non-MS, n = 6) and stored at −80°C as described previously (45–47). Brain 
samples from MS and non-MS patients were obtained from the Laboratory 
for Neurological Infection and Immunity Brain Bank, University of Alberta. 
Normal-appearing frontal white matter was homogenized, lysed in TRIzol 
(Invitrogen), and used in real-time PCR analyses as described previously 
(48). The MS patient group (female/male, 4:2) was classifi  ed as relapsing-
  remitting (n = 1), primary progressive (n = 2), and secondary progressive 
(n = 3; mean age 57 ± 10 yr) with estimated disability status scores of 7–10 
at death. The non-MS group (female/male, 3:3) was classifi  ed as anoxic en-
cephalopathy (n = 1), HIV-1 infection (encephalitis, n = 1; toxoplasmosis 
encephalitis, n = 1), Alzheimer’s disease (n = 2), and sepsis (n = 1; mean age 
61 ± 12 yr). Human CNS sections from non-MS and MS patients with 
acute demyelinating lesions were provided by A. Clark (University of Cal-
gary, Calgary, Canada).
Cell cultures. Mouse primary astrocyte cultures were established from 
CNS tissue of 2-d-old PAR2 WT and KO mice as described previously (49). 
Cells were cultured in MEM containing 10% FBS, 1 mM sodium pyruvate, 
and 2 mM l-glutamine. Mouse bone marrow–derived macrophages were 
isolated from the pelvic and femoral bone marrow of adult PAR2 WT and 
KO mice (50) as described previously (47, 51). Bone marrow cells were cul-
tured in DMEM containing 10% FBS, 10% L929 cell–conditioned medium 
as a source of M-CSF, and 2 mM l-glutamine (Invitrogen). Cells were incu-
bated in 10% CO2 for 5 d before additional treatments. Macrophages or 
  astrocytes were treated with 100 ng/ml LPS for 8 h before TRIzol lysis 
and RNA extraction. For PAR2 activation experiments, cells were treated 
with 100 μM PAR2 AP (SLIGRL-NH2) or mAP (LSIGRL-NH2) for 4 h 
(Peptide Synthesis Facility, University of Calgary). Cells were then washed 
twice and fresh AIM-V serum-free medium (Invitrogen) was added. Media 
was harvested 24 h later and stored at −80°C for subsequent oligodendrocyte 
toxicity experiments. Oligodendrocytes were isolated from adult Sprague-
Dawley rat brains and plated in polyornithine-coated chamber slides (Nunc) 
as described previously (52). Oligodendrocytes were maintained in MEM 
containing 5% FBS, 0.1% dextrose, 2 mM l-glutamine, and 1 mM sodium 
pyruvate for 5 d. Oligodendrocytes were then treated with the supernatants 
of PAR2 AP–treated macrophages or astrocytes for 24 h before fi  xation and 
immunostaining. Human PBMCs from healthy individuals were isolated by 
density separation over Ficoll-hypaque and seeded in 24-well plates in RPMI 
containing 10% FBS. Cells were treated with 5 μg/ml phytohemagglutinin 
for 24 h before staining and fl  ow cytometric analysis.
Immunohistochemistry. Formalin-fi  xed, paraffi   n-embedded sections of 
human brain tissue (frontal lobe) were deparaffi   nized and rehydrated using 
decreasing concentrations of ethanol. Antigen retrieval was performed by 
boiling the slides in 0.01 M trisodium citrate buff  er, pH 6, for 10 min fol-
lowed by incubation with 0.3% hydrogen peroxide to block endogenous 
peroxidases. Sections were then preincubated with 10% normal goat serum, 
0.2% Triton X-100 overnight at 4°C to block nonspecifi  c binding. To de-
tect PAR2 immunoreactivity, slides were incubated overnight at 4°C with a 
rabbit polyclonal antibody (B5) raised against rat PAR2 (1:500; reference 53) 
(GPN SKG RSL IGR LDT 46P YGG C; 1/500) diluted in 5% normal goat 
serum, 0.2% Triton X-100 (47). A secondary biotinylated goat anti–rabbit 
antibody followed by avidin–biotin–peroxidase complexes (Vector Labora-
tories) and 3,3′-diaminobenzidine tetrachloride (Vector Laboratories) were 
used for single labeling. For double labeling with anti-CD45 (1:100; Zymed 
Laboratories) and anti-GFAP (1:50; BD Biosciences) mouse monoclonal 
  antibodies, an alkaline phosphatase–conjugated goat anti–mouse antibody 
(Jackson ImmunoResearch Laboratories) followed by NBT/BCIP substrate 
(Vector Laboratories) were used.
Immunofl   uorescence and confocal laser scanning microscopy. 
  Rabbit polyclonal anti-PAR2 (B5) antibody (53) together with mouse mono-
clonal anti-GFAP (1:50; BD Biosciences) and goat polyclonal anti-PAR2 
antibody (1:50; Santa Cruz Biotechnology, Inc.) together with rabbit poly-
clonal antibody against Iba-1 (1:500; Wako) followed by appropriate 
  secondary antibodies were used to detect PAR2 immunoreactivity and 
localization in lumbar spinal cords of mice (47). Antibodies against Iba-1 
(1:500; Wako), CD3 (1:100; Santa Cruz Biotechnology, Inc.), and MBP 
(1:1,000; Sternberger Monoclonals) followed by appropriate secondary anti-
bodies were used to detect macrophage/microglial, T lymphocyte, and my-
elin immunoreactivity. Slides were examined on an Olympus Fluoview 
(FV300) confocal laser scanning microscope. For quantifi  cation, Iba-1 or 
CD3-immunopositive cells were counted using a regular fl  uorescent micro-
scope (Axioskop2; Carl Zeiss MicroImaging, Inc.) in ventral, lateral, and 
dorsal columns of the spinal cord white matter. Quantitative analysis of MBP 
reactivity was performed using Scion Image software (Scion Corporation). 
Cultured oligodendrocytes derived from adult rat brains were stained with 
O1 anti-galactocerebroside monoclonal antibody (provided by V.W. Yong, 
University of Calgary, Calgary, Canada) that recognizes mature oligoden-
drocytes, followed by a Cy3-conjugated goat anti–mouse antibody. Slides 
were scanned by laser scanning confocal microscope, and Scion Image soft-
ware was used to measure the surface area of O1-immunopositive oligoden-
drocytes (52).
Real-time RT-PCR. Cultured cells, human brain (frontal lobe white 
matter), or lumbar spinal cords from mice were homogenized in TRIzol 
(Invitrogen) according to the manufacturer’s guidelines. Total RNA 
was isolated and dissolved in diethylpyrocarbonate-treated water, and 
1 μg RNA was used for the synthesis of complementary DNA and sub-
sequent PCR as described previously (48). Primer sequences were as 
follows: human GAPDH, 5′ primer: 5′-A  G  C  C  T  T  C  T  C  C  A  T  G  G  T  G  G  T-
G  A  A  G  A  C  -3′,3′primer: 5′-C  G  G  A  G  T  C  A  A  C  G  G  A  T  T  T  G  G  T  C  G  -3′; hu-
man PAR2, 5′ primer: 5′-C  T  G  G  C  C  A  T  T  G  G  G  G  T  C  T  T  T  C  T  G  T  T  C  -3′, 
3′ primer: 5′-G  G  C  C  C  T  C  T  T  C  C  T  T  T  T  C  T  T  C  T  C  T  G  A  -3′; human tryp-
sinogen, 5′ primer: 5′-T  C  A  G  C  G  A  A  C  A  G  T  G  G  G  T  G  G  T  A  T  C  A  G  -3′, 3′ 
primer: 5′-G  A  G  G  G  G  C  G  G  T  G  G  G  C  A  G  A  G  -3′; mouse PAR2, 5′ primer: 
5′-TGGCCATTGGAGTCTTCCTGTT-3′,   3′  primer:   5′-TAGCC-
CTCTGCCTTTTCTTCTC-3′; and mouse trypsinogen, 5′ primer: 
5′-ATCTCTGGCTGGGG  CAACA  C  T  C-3′, 3′ primer: 5′-CTAGGAA-
G  C  C  A  G  C  A  C  A  G  A  C  C  A   T-3′. Mouse trypsinogen primers were designed 434  PAR2 MODULATES NEUROINFLAMMATION IN MS AND EAE | Noorbakhsh et al.
based on the mouse mesotrypsin (mouse serine protease 3, Prss3) sequence. 
The other mouse oligonucleotide primer sequences have been reported pre-
viously (54). Semiquantitative analysis was performed by monitoring in real 
time the increase of fl  uorescence of the SYBR green dye on an i-Cycler 
(Bio-Rad Laboratories) as reported previously (48). All data were normal-
ized against the GAPDH mRNA levels and expressed as fold increases rela-
tive to controls ± SE.
Induction and assessment of EAE. 10–12-wk-old female PAR2 homo-
zygous KO mice (50) and littermate homozygous WT controls were used 
for EAE induction. Age-matched female mice were injected subcutaneously 
with 50 μg MOG (MOG35–55 peptide; prepared by the Peptide Synthesis 
Facility, University of Calgary) emulsifi  ed in 100 μl of complete Freund’s 
adjuvant (Difco Laboratories; reference 47). Animals received intraperitoneal 
injections of pertussis toxin (0.3 μg; List Biological Laboratories) at the same 
time as MOG immunization and 48 h later. Vehicle-treated animals were 
only injected with complete Freund adjuvant and pertussis toxin. Animals 
were assessed daily for EAE severity for 30 d using a 0–5 rating scale as re-
ported previously (55). Animals were killed by cardiac puncture under ket-
amine/xylazine anesthesia. Spinal cords were removed and fi   xed in 4% 
neutral buff  ered formalin before paraffi   n embedding or lysed in TRIzol for 
RNA extraction. All experiments were approved by the University of 
  Calgary Animal Care Committee.
Histological analysis. Formalin-fi   xed spinal cords of EAE or vehicle-
treated animals were embedded in paraffi   n before sectioning (56). 4-μm sec-
tions from lumbar spinal cords were stained with Bielschowsky’s silver 
impregnation method (33). Five randomly chosen fi  elds in each animal’s 
white matter were scanned and photographed using a microscope (Axios-
kop2; Carl Zeiss MicroImaging, Inc.) and the Spot imaging system (Diag-
nostic Instruments). The number of silver-positive axons was quantifi  ed in 
square millimeters using Scion Image software (Scion Corporation).
T cell proliferation and fl  ow cytometric analysis. Splenocytes isolated 
from the spleens of nonimmunized animals by density separation over Ficoll-
hypaque were γ irradiated, suspended at a density of 2 × 106 cells/ml, and 
incubated with 40 μg/ml MOG35–55 peptide for 30 min (57). Splenocytes 
incubated with vehicle were used as control. Draining lymph nodes were 
isolated from MOG-immunized PAR2 WT and KO animals 7 d after im-
munization. Lymph nodes were homogenized in PBS, and lymphocytes iso-
lated from dissociated lymph nodes were washed and suspended at a density 
of 2 × 106 cells/ml. Splenocytes and lymphocytes were plated 1:1 in 96-well 
U-bottom microtiter plates. Cells were incubated at 37°C for 48 h before 
adding 1 μCi [3H]thymidine (GE Healthcare) to each well. Cells were har-
vested after 24 h and counted on a liquid scintillation counter. Intracellular 
cytokine assay was performed using a cytofi  x/cytoperm kit according to the 
manufacturer’s guidelines (BD Biosciences). In brief, Golgistop protein 
transport inhibitor was added to splenocyte/lymphocyte cocultures 48 h 
  after plating. Cells were harvested after 12 h and immunostained using PerCP-
labeled anti–mouse CD3 (1:50), FITC-labeled anti–mouse CD4 (1:50), and 
PE-labeled anti–IFN-γ (1:50) monoclonal antibodies. All monoclonal anti-
bodies were purchased from BD Biosciences. For PAR2 immunodetection, 
cultured PBMCs were stained with B5 rabbit anti-PAR2 antibody followed 
by Alexa 488–conjugated goat anti–rabbit secondary antibody. FACS analy-
sis was performed on a FACSCalibur apparatus using CELLQuest software 
(Becton Dickinson).
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